![](/images/2013/post-sep.jpg)
Travere Therapeutics to Present at the 2024 Cantor Global Healthcare Conference
/EIN News/ -- SAN DIEGO, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that company management will present at the 2024 Cantor Global Healthcare Conference on Tuesday, September 17, 2024, at 9:45 a.m. ET.
A live webcast will be accessible on the Investor page of Travere’s website at ir.travere.com/events-presentations, and a replay will be available for up to 30 days following the event.
About Travere Therapeutics
At Travere Therapeutics, we are in rare for life. We are a biopharmaceutical company that comes together every day to help patients, families, and caregivers of all backgrounds as they navigate life with a rare disease. On this path, we know the need for treatment options is urgent – that is why our global team works with the rare disease community to identify, develop, and deliver life-changing therapies. In pursuit of this mission, we continuously seek to understand the diverse perspectives of rare patients and to courageously forge new paths to make a difference in their lives and provide hope – today and tomorrow. For more information, visit travere.com.
Contact:
Investors: 888-969-7879 IR@travere.com |
Media: 888-969-7879 mediarelations@travere.com |
![](https://ml.globenewswire.com/media/Zjg4ZGQzMzUtYTNlOC00Y2JiLWFjYmUtOGFlMTNlMDhiMWEyLTEwMTU4NDQ=/tiny/Travere-Therapeutics-Inc-.png)
![](https://health.einnews.com/tracking/article.gif?aid=742360889§ion=globenewswire&a=qt6DmLMS0v_hNCdn&i=fzmmgSTEvPKT0c7H)
Distribution channels: Culture, Society & Lifestyle, Healthcare & Pharmaceuticals Industry ...
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Submit your press release